To contrast, across all patients, the transcriptionally defined “leukemia” cells were comprised of cells from heterogeneous immunophenotypic subpopulations, with the greatest contributions from cells with stem or myeloid markers, including CD34+/CD13+ cells (12.89% of leukemia population), CD34+/CD117+ cells (12.86%), CD33+/CD64+ cells (11.60%), and CD34+/CD33+/CD117+ cells (11.20%). This evidence concerns the gene CD33 and leukemia.